Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747113 | 0.83 | ALDH1A1 (0.50) | CYP1A2CYP2A6ALDH1A1BACE1HSD17B10 | |
| SCHEMBL23313172 | 0.77 | TNKS2 (0.46) | CYP1A2CYP2A6ALDH1A1BACE1HSD17B10 | |
| SCHEMBL21698475 | 0.77 | MAOA (0.44) | ALDH1A1BACE1HSD17B10CYP3A4HPGD | |
| SCHEMBL29487594 | 0.76 | ALDH1A1 (0.54) | CYP1A2CYP2A6ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL7218852 | 0.76 | ALDH1A1 (0.48) | CYP1A2CYP2A6ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL29352143 | 0.76 | CYP1A2 (1.00) | CYP1A2CYP2A6ALDH1A1BACE1HSD17B10 | |
| SCHEMBL598829 | 0.76 | CYP1A2 (1.00) | CYP1A2CYP2A6ALDH1A1BACE1HSD17B10 | |
| SCHEMBL2153752 | 0.76 | ALDH1A1 (0.54) | CYP1A2CYP2A6ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL14100536 | 0.76 | CYP1A2 (0.63) | CYP1A2CYP2A6ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL1402233 | 0.74 | CYP1A2 (0.64) | CYP1A2CYP2A6ALDH1A1BACE1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104230728-B | 1,2-diketone naphthalene compounds and preparation method and application | 山东大学 | 2016-08-24 | — | — | CN | claimed |
| US-20230380264-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION | 2023-11-23 | — | — | US | disclosed |
| EP-3722301-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-11-01 | — | — | EP | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4223761-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022262686-A1 | KRAS G12D INHIBITORS | JINGRUI BIOPHARMA CO., LTD. (CN) | 2022-12-22 | — | — | WO | disclosed |
| WO-2021139678-A1 | PYRIDOPYRIMIDINE KRAS G12C MUTANT PROTEIN INHIBITOR | 广州百霆医药科技有限公司 | 2021-07-15 | — | — | WO | disclosed |
| WO-2021063346-A1 | KRAS G12C INHIBITOR AND APPLICATION THEREOF | 上海迪诺医药科技有限公司 | 2021-04-08 | — | — | WO | disclosed |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2021-02-23 | — | — | US | disclosed |
| EP-1352906-A1 | COMPOSITIONS FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Sankyo Company, Limited (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1243589-A1 | Heteroaryl-substituted pyrrole derivates, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6441131-B1 | SYNTHETIC PEPTIDES WITH TERMINAL ANILINE, AMINOCOUMARINE, OR AMINONAPHTHALENE DERIVATIVE RESIDUE AS SUBSTRATE FOR HUMAN PEPSIN OR PEPSINOGEN; DIAGNOSIS OF GASTROINTESTINAL DISORDERS SUCH AS GASTRIC CANCER OR GASTRIC ULCERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-27 | — | — | US | disclosed |
| US-20020099019-A1 | Peptides, methods for assaying human pepsinogen I or human pepsin I and assay kits | HAYASHI AKIO (JP) | 2002-07-25 | — | — | US | disclosed |
| WO-2002057264-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO COMPANY LIMITED (JP) | 2002-07-25 | — | — | WO | disclosed |
| US-6407206-B1 | PEPTIDE SUBSTRATE AND OLIGOPEPTIDES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1070711-A2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
| EP-1046650-A1 | PEPTIDES, METHOD FOR ASSAYING HUMAN PEPSINOGEN II or HUMAN PEPSIN II, AND ASSAYING KIT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-10-25 | — | — | EP | disclosed |
| EP-0959078-A1 | PEPTIDES, METHODS FOR ASSAYING HUMAN PEPSINOGEN I OR HUMAN PEPSIN I, AND ASSAY KITS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-11-24 | — | — | EP | disclosed |
| US-4008326-A | INCREASING PRODUCTION OF PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | CYP1A2 1836/4885CYP2A6 3522/4885ALDH1A1 2326/4885 |
| US-20020099019-A1 | Peptides, methods for assaying human pepsinogen I or human pepsin I and assay kits | ANPEP, DAO, ARGLU1 | CYP1A2 1623/4885CYP2A6 1891/4885ALDH1A1 2289/4885 |
| US-20230380264-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | TIMCC, ICOSLG, NUDT1 | CYP1A2 3531/4885CYP2A6 4576/4885ALDH1A1 2471/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CYP1A2 3408/4885CYP2A6 3163/4885ALDH1A1 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.